At what enterprise value was HEART & LUNG IMAGING acquired in 2022?

You can find the full valuation details of HEART & LUNG IMAGING on mynth capital. The transaction's Enterprise Value is estimated to be in the range of 20M - 50M USD. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of HEART & LUNG IMAGING when it was acquired by RADNET?

The exact EV/EBITDA multiple for HEART & LUNG IMAGING is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was HEART & LUNG IMAGING acquired by RADNET?

HEART & LUNG IMAGING was acquired by RADNET in 2022.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the HEART & LUNG IMAGING acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the HEART & LUNG IMAGING deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.radnet.com/about-radnet/news/radnet-acquires-controlling-interest-heart-lung-imaging-limited-london-based

← DATABASE

Home Database Healthcare & PharmaHEART & LUNG IMAGING

11/2022

RADNET takes majority stake in HEART & LUNG IMAGING

UNITED KINGDOM Health Providers / Outpatient Care / Radiology EV 20M - 50M USD

Context

RadNet, a US-based medical imaging specialist, has acquired a 75% majority stake in Heart & Lung Imaging Limited (HLH), a UK-based teleradiology network focused on detecting and diagnosing lung and cardiovascular diseases. This move is part of RadNet's strategy to enhance its capabilities in early cancer detection and develop solutions that combine artificial intelligence (AI) with specialized medical expertise. Through this acquisition, RadNet expands its presence in the UK and positions itself in a market with significant growth prospects, driven in part by the National Health Service's (NHS) Targeted Lung Health Check (TLHC) program. This lung cancer screening program, targeting high-risk populations aged 55-74 with a history of smoking, is expected to generate over one million lung scans per year in England. By integrating HLH, RadNet can leverage its new partner's image reading and interpretation capabilities, combined with the AI technologies developed by its Dutch subsidiary Aidence, which specializes in automated lung nodule detection. The acquisition also aims to accelerate the deployment of large-scale population screening programs, a strategic segment for RadNet. By combining AI tools with the expertise of specialized radiologists, the company seeks to improve diagnostic accuracy, reduce unnecessary patient recalls, and optimize healthcare costs. Beyond the UK, this platform could serve as a model for developing similar programs in the US and other international markets.

HEART & LUNG IMAGING, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Heart & Lung Imaging Limited is a UK-based teleradiology network dedicated to enhancing clinical outcomes for pulmonary and cardiovascular diseases through early diagnosis and specialized medical expertise. Headquartered in London, the company leverages a national network of over 70 expert cardiothoracic radiologists who provide imaging interpretation services to the National Health Service (NHS), as well as numerous hospitals, academic centers, and medical institutions across the UK. The company has established itself as the primary independent provider of radiology reading services for the NHS England Targeted Lung Health Check (TLHC) program, one of Europe's largest lung cancer screening initiatives. Its core activity involves analyzing low-dose thoracic computed tomography (CT) scans to identify lung cancers and other respiratory pathologies at an early stage. This expertise is particularly crucial given that lung cancer remains a leading cause of mortality in the UK, with approximately 48,000 new cases diagnosed annually.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2022

2021

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
06/2023	PARQUEST CAPITAL	IMANEO	FRANCE	Health Providers	Parquest acquired a majority stake in the newly formed Imaneo group from its 70 associate radiologists. The transaction was the result of a competitive process involving both French and international private equity funds, as well as corporate interest from the life sciences sector
06/2023	ARDIAN	MON VETO	FRANCE	Health Providers	Ardian acquired a minority stake (approximately 20%) in Mon Veto through a primary capital increase. This "pure cash-in" operation was designed to strengthen the group's equity base without any cash-out for the founding veterinarians
10/2022	CBPE CAPITAL	VEINCENTRE	UNITED KINGDOM	Health Providers	CBPE Capital has completed a majority investment in Veincentre, acquiring the stake previously held by Palatine Private Equity alongside the company,s founders. This transaction marks a secondary LBO for the specialist clinic group, which saw significant growth under Palatine,s three-year ownership, including the expansion from 7 to 22 clinics
09/2022	EURAZEO	IMAPOLE	FRANCE	Health Providers	Eurazeo has partnered with Bpifrance to complete a major investment of over EUR 50 million in Imapole. This investment marks a strategic turning point in the professionalization of regional medical imaging groups in France
09/2022	ORADIANSE	REVEL	FRANCE	Health Providers	Oradianse, a leading group of radiologists, has acquired a radiology practice in Revel, located in the Haute-Garonne region near Toulouse. This move is part of the company's territorial development strategy, aimed at strengthening its presence in the Occitanie region and consolidating its national network of medical imaging centers
08/2022	FREEMAN SPOGLI	EVERVET PARTNERS	UNITED STATES	Health Providers	Freeman Spogli & Co. made a significant investment in EverVet Partners, partnering alongside existing investor Tailwind Capital while EverVet's founders and management retained meaningful equity stakes
07/2022	INFRAVIA CAPITAL	UNIVET	FRANCE	Health Providers	InfraVia Capital Partners acquired a minority stake in Univet from Platina Equity Solutions, which had been a partner since 2018. The transaction was structured as a combination of secondary share purchases and a primary capital increase, financed entirely through equity from InfraVia's EUR5 billion European Fund V
07/2022	LATOUR CAPITAL	PHARMACIE LAFAYETTE - GROUPE HYGIE31	FRANCE	Health Providers	Latour Capital and Bpifrance acquired a majority stake in Hygie31, the holding company of Pharmacie Lafayette, from Five Arrows (Rothschild & Co). The deal aims to accelerate the group's development in France and Europe through organic growth and an ambitious buy-and-build strategy
07/2022	ANDERA PARTNERS	GROUPE RESONANCE IMAGERIE	FRANCE	Health Providers	R�sonance Imagerie, a prominent French medical imaging group, has secured a major financing package from Andera MidCap, Ardian Private Debt, and Five Arrows Debt Partners. Established in 2011, the group currently operates a network of 15 centers across Paris, �le-de-France, and the Centre-Val-de-Loire region, managing 23 high-tech units including MRIs and scanners
06/2022	EURAZEO	SEVETYS	FRANCE	Health Providers	Eurazeo acquired a majority stake in Sevetys from Ardian, which had previously financed the group's initial rapid expansion. The transaction included a EUR250 million equity injection from Eurazeo to fuel a new phase of aggressive growth

REFERENCES

Valuation range: EV 20M - 50M USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HEART & LUNG IMAGING by RADNET are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: heart & lung imaging